Magnitude Study
- Study HIC#:2000036310
- Last Updated:05/01/2025
A phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled study that aims to evaluate the efficacy of NTLA-2001, in participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM), as measured by the composite risk of cardiovascular-related mortality and cardiovascular events (urgent heart failure visits and hospitalizations due to heart failure, myocardial infarct, arrhythmia, or stroke), compared to placebo.
MAGNITUDE Study | transthyretin amyloidosis with cardiomyopathy clinical trial | Learn More
Contact Us
For more information about this study, including how to volunteer, contact:
Cinthia de Freitas
- Phone Number: 1-203-785-2776
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
If you are between the ages of 18 and 90, diagnosed with heart failure due to ATTR, on medication for heart failure and have experienced heart failure symptoms in the past year, men or women who can no longer have children, you may qualify to participate in this study. *** Other criteria apply. Please contact the Research Coordinator to see if you qualify for this study.
